Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 4:45 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 5,272 matching trials from the live ClinicalTrials.gov search.
Filters: Gainesville, Florida Clear all
Active, not recruiting Phase 2 Interventional Results available

Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer

NCT04001829
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
Docetaxel, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older · Female only
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
482
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 309 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 1, 2026, 4:45 PM EST
Completed No phase listed Observational

Developing Self-Management Interventions After HCT

NCT03710031
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplant (HSCT)
Interventions
PNS Tracking
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced Nov 1, 2026, 4:45 PM EST
Completed Phase 2 Interventional Results available

NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)

NCT05005845
View directory record Official record
Conditions
Cutaneous Neurofibroma, Neurofibromatosis 1
Interventions
NFX-179 gel, Vehicle gel
Drug
Lead sponsor
NFlection Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
23
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Fremont, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Nov 1, 2026, 4:45 PM EST
Recruiting Not applicable Interventional

Wearable Focal Vibration Therapy on Upper Extremity Function of People With Multiple Sclerosis: A Pilot Study

NCT07376772
View directory record Official record
Conditions
Multiple Sclerosis (MS) - Relapsing-remitting, Upper Extremity Dysfunction
Interventions
wearable focal vibration therapy
Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Nov 1, 2026, 4:45 PM EST
Completed Phase 2 Interventional

A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients With Erosive Esophagitis.

NCT00206245
View directory record Official record
Conditions
GERD With Erosive Esophagitis
Interventions
AZD0865
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
77
States / cities
Alabaster, Alabama • Huntsville, Alabama • Tucson, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2013 · Synced Nov 1, 2026, 4:45 PM EST
Completed Phase 3 Interventional Results available

A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A

NCT04161495
View directory record Official record
Conditions
Factor VIII Deficiency
Interventions
efanesoctocog alfa (BIVV001)
Biological
Lead sponsor
Bioverativ, a Sanofi company
Industry
Eligibility
12 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • Gainesville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Nov 1, 2026, 4:45 PM EST
Completed Phase 4 Interventional Results available

Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study

NCT02406677
View directory record Official record
Conditions
Cost Sharing, Acute Coronary Syndrome
Interventions
Study voucher card
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
11,001 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
271
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 224 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Nov 1, 2026, 4:45 PM EST
Withdrawn Not applicable Interventional

SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients With Type 1 and Type 2 Diabetes

NCT06719531
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
Continuous Glucose Monitoring
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
11 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
28
States / cities
Birmingham, Alabama • Chula Vista, California • Concord, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Nov 1, 2026, 4:45 PM EST
Active, not recruiting Phase 3 Interventional

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

NCT05566795
View directory record Official record
Conditions
Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma
Interventions
Tovorafenib, Chemotherapeutic Agent
Drug
Lead sponsor
Day One Biopharmaceuticals, Inc.
Industry
Eligibility
Up to 25 Years
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 1, 2026, 4:45 PM EST
Completed Phase 3 Interventional Results available

Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)

NCT00509795
View directory record Official record
Conditions
Macular Degeneration
Interventions
ranibizumab, aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
1,217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
176
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 144 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2012 · Synced Nov 1, 2026, 4:45 PM EST
Terminated No phase listed Observational

Establishment of a PDT Patient Registry

NCT03589456
View directory record Official record
Conditions
Lung Cancer
Interventions
No intervention
Other
Lead sponsor
Concordia Laboratories Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Timeline
2019 – 2020
U.S. locations
10
States / cities
Concord, California • Los Angeles, California • Gainesville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Nov 1, 2026, 4:45 PM EST
Completed Not applicable Interventional Results available

Safety and Effectiveness of B-Laser™ in Subjects Affected With Infrainguinal PAD

NCT03157531
View directory record Official record
Conditions
PAD
Interventions
B-Laser™ Atherectomy System
Device
Lead sponsor
Eximo Medical Ltd.
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
8
States / cities
Little Rock, Arkansas • Altamonte Springs, Florida • Bradenton, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2019 · Synced Nov 1, 2026, 4:45 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Neurophysiologic Signatures of Trigeminal Neuralgia Pain

NCT03778177
View directory record Official record
Conditions
Trigeminal Neuralgia (TN)
Interventions
transcranial electrical brain stimulation
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Nov 1, 2026, 4:45 PM EST
Completed Not applicable Interventional Results available

ILUMIEN IV: OPTIMAL Percutaneous Coronary Intervention (PCI)

NCT03507777
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Stenosis, Atherosclerosis, STEMI, STEMI - ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI)
Interventions
Coronary PCI guided by OCT, Coronary PCI guided by Angiography
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,487 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
42
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Burlingame, California + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Nov 1, 2026, 4:45 PM EST
Terminated Phase 3 Interventional

Ribavirin to Prevent RSV Pneumonia in Bone Marrow Transplant Patients

NCT00031473
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
Virazole (Ribavirin) Inhalation Solution
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years to 60 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
11
States / cities
Birmingham, Alabama • Duarte, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Nov 1, 2026, 4:45 PM EST
Completed Phase 3 Interventional Results available

Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures

NCT00520741
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
16 Years to 70 Years
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
108
States / cities
Alabaster, Alabama • Birmingham, Alabama • Huntsville, Alabama + 93 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Nov 1, 2026, 4:45 PM EST
Completed Phase 2 Interventional Results available

Crossover Trial of AD109 in Obstructive Sleep Apnea

NCT04580394
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
AD109, Atomoxetine, R-oxybutynin, Placebo, Digit System Substitution Test
Drug · Diagnostic Test
Lead sponsor
Apnimed
Industry
Eligibility
25 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Little Rock, Arkansas • Pomona, California • New Haven, Connecticut + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Nov 1, 2026, 4:45 PM EST
Recruiting Phase 3 Interventional

A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation

NCT07759154
View directory record Official record
Conditions
Attention-deficit/Hyperactivity Disorder, Emotional Dysregulation
Interventions
Centanafadine XR
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
16
States / cities
Gainesville, Florida • Jacksonville, Florida • Maitland, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 1, 2026, 4:45 PM EST
Terminated Not applicable Interventional Results available

LVRC IDE Crossover Study (Crossover From IDE Trial CLN0009)

NCT02059057
View directory record Official record
Conditions
Emphysema
Interventions
LVRC System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
36 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • Mountain View, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Nov 1, 2026, 4:45 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Written Exposure Therapy to Improve Lives After Stress Exposure

NCT05390775
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Written Exposure Therapy (WISE), Non-emotional Writing
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
6
States / cities
Gainesville, Florida • Indianapolis, Indiana • Worcester, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Nov 1, 2026, 4:45 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Comparative Effectiveness of Mobile Health Smoking Cessation Approaches Among Underserved Patients in Primary Care

NCT05415761
View directory record Official record
Conditions
Tobacco Use Cessation
Interventions
iCanQuit, iCanQuit+Motiv8, Florida quit line
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
21 Years and older
Enrollment
1,332 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Nov 1, 2026, 4:45 PM EST
Terminated Phase 2Phase 3 Interventional Results available

Safety and Efficacy Study in Infant With SBS

NCT02865122
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
NTRA-9620, Placebo
Drug
Lead sponsor
Elgan Pharma Ltd.
Industry
Eligibility
2 Weeks to 52 Weeks
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
8
States / cities
Palo Alto, California • Hartford, Connecticut • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Nov 1, 2026, 4:45 PM EST
Not listed Not applicable Interventional

Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs

NCT01365429
View directory record Official record
Conditions
Lung Transplant
Interventions
XPS™ with Steen Solution™
Device
Lead sponsor
XVIVO Perfusion
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
18
States / cities
Los Angeles, California • Aurora, Colorado • Gainesville, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Nov 1, 2026, 4:45 PM EST
Completed Not applicable Interventional

The Acute Burn ResUscitation Multicenter Prospective Trial

NCT04356859
View directory record Official record
Conditions
Burn Injury
Interventions
Albumin Human
Drug
Lead sponsor
American Burn Association
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
24
States / cities
Phoenix, Arizona • Sacramento, California • Torrance, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Nov 1, 2026, 4:45 PM EST